Calcineurin inhibitors revisited: A new paradigm for COVID-19?

Link to article at PubMed

Hage R, et al. Braz J Infect Dis 2020.

ABSTRACT

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than viral load. Therapies for COVID-19 are investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment in COVID-19, based on the experience seen in solid organ transplant recipients who suffered from COVID-19.

PMID:32603679 | DOI:10.1016/j.bjid.2020.06.005

Leave a Reply

Your email address will not be published.